Deficiency of Both Farnesoid X Receptor and Takeda G Protein–Coupled Receptor 5 Exacerbated Liver Fibrosis in Mice
Open accessAbstract
Activation of the nuclear bile acid receptor farnesoid X receptor (FXR) protects against hepatic inflammation and injury, while Takeda G protein–coupled receptor 5 (TGR5) promotes adipose tissue browning and energy metabolism. Here, we examined the physiological and metabolic effects of the deficiency of these two bile acid receptors on hepatic metabolism and injury in mice. Fxr/Tgr5 double knockout mice (DKO) were generated for metabolic phenotyping. Male DKO mice fed a chow diet had reduced liver lipid levels but increased serum cholesterol levels. Liver cholesterol 7α‐hydroxylase ( Cyp7a1 ) activity and sterol 12α‐hydroxylase mRNA levels were induced, while ileum FXR target genes were suppressed in DKO mice compared to wild‐type (WT) mice. Bile acid pool size was increased in DKO mice, with increased taurocholic acid and decreased tauromuricholic acids. RNA sequencing analysis of the liver transcriptome revealed that bile acid synthesis and fibrosis gene expression levels are increased in chow‐fed DKO mice compared to WT mice and that the top regulated pathways are involved in steroid/cholesterol biosynthesis, liver cirrhosis, and connective tissue disease. Cholestyramine treatment further induced Cyp7a1 mRNA and protein in DKO mice and increased bile acid pool size, while cholic acid also induced Cyp7a1 in DKO mice, suggesting impaired bile acid feedback regulation. A Western diet containing 0.2% cholesterol increased oxidative stress and markers of liver fibrosis but not hepatic steatosis in DKO mice. Conclusion: FXR and TGR5 play critical roles in protecting the liver from inflammation and fibrosis, and deficiency of both of these bile acid receptors in mice increased cholic acid synthesis and the bile acid pool, liver fibrosis, and inflammation; FXR and TGR5 DKO mice may be a model for liver fibrosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FXR is a promising therapeutic target for nonalcoholic steatohepatitis (NASH) and liver fibrosis.
“Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 30 · Cited by 65
- Authors
- Ferrell, J. M., Pathak, P., Boehme, S., Gilliland, T., & Chiang, J. Y. L.
- Affiliations
- Northeast Ohio Medical University (US)
- Corresponding author
- Chiang, John Y. L.
- Venue
- Hepatology
- Published
- 2019-03-22
- Volume
- 70
- Issue
- 3
- Pages
- 955-970
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC6642864
- OpenAlex
- W2914212388
- Cited by
- 65
- References
- 30
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 7 · 2023: 9 · 2022: 6 · 2021: 16 · 2020: 8 · 2019: 5
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5r01dk044442-26, DK58379, DK44442)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK-044442, R01DK058379, R56DK044442, R37DK058379)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- farnesoid X receptor, TGR5, bile acid receptors, liver fibrosis, bile acid synthesis, CYP7A1, bile acid pool, liver inflammation, oxidative stress, cholestyramine, Western diet, cholesterol
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Biopsy, Needle, Cholesterol 7-alpha-Hydroxylase, Disease Models, Animal, Fatty Liver, Gene Expression Regulation, Immunohistochemistry, Liver Cirrhosis, Male, Mice, Inbred C57BL, Random Allocation, Signal Transduction, Receptors, Cytoplasmic and Nuclear, Mice, Knockout, Oxidative Stress, Disease Progression, Cholic Acid, Receptors, G-Protein-Coupled, Mice, Diet, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review